| Phase 15 trials |
|
Phase 1
|
NCT02860650 |
Aug 2016 → May 2017 |
— |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02376400 |
Apr → Dec 2015 |
— |
Crucell Holland BV |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02376426 |
Mar → Sep 2015 |
— |
Crucell Holland BV |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02325050 |
Jan → Jul 2015 |
— |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02313077 |
Dec 2014 → Apr 2015 |
— |
Crucell Holland BV |
Completed
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT05284097 |
Sep 2022 → Mar 2023 |
Ebola hemorrhagic fever |
London School of Hygiene and Tropical Medicine |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05064956 |
Oct → Nov 2021 |
Ebola hemorrhagic fever, HIV infectious disease |
London School of Hygiene and Tropical Medicine |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04711356 |
Jul → Sep 2021 |
Ebola hemorrhagic fever |
London School of Hygiene and Tropical Medicine |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04186000 |
Dec 2019 → Apr 2020 |
Ebola hemorrhagic fever |
University of Antwerp |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03929757 |
Aug 2019 → Aug 2022 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02876328 |
Mar 2017 → Dec 2019 |
Ebola hemorrhagic fever |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02598388 |
Dec 2015 → Dec 2018 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02564523 |
Nov 2015 → Feb 2019 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02416453 |
Jun 2015 → Jan 2018 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
| Phase 38 trials |
|
Phase 3
|
NCT06126822 |
Feb 2025 → Oct 2026 expected |
Ebola hemorrhagic fever |
Institute of Tropical Medicine, Belgium |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04556526 |
Oct 2020 → Mar 2023 |
— |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04228783 |
Feb 2020 → Apr 2022 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04152486 |
Nov 2019 → Jan 2022 |
Ebola hemorrhagic fever |
London School of Hygiene and Tropical Medicine |
Unknown
|
No outcome recorded
|
|
Phase 3
|
NCT02661464 |
May 2016 → Dec 2021 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT02509494 |
Sep 2015 → Jun 2019 |
Ebola hemorrhagic fever |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02543567 |
Sep 2015 → Jun 2016 |
— |
Janssen Vaccines & Prevention B.V. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02543268 |
Sep 2015 → Jan 2016 |
— |
Crucell Holland BV |
Completed
|
No outcome recorded
|